TE
Tema ETFs Portfolio holdings
AUM
$377M
This Quarter Return
-1.1%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$241M
AUM Growth
–
Cap. Flow
+$241M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
27.78%
Holding
148
New
148
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Rockwell Automation
ROK
|
$9.12M |
| 2 |
Applied Industrial Technologies
AIT
|
$8.13M |
| 3 |
Primoris Services
PRIM
|
$7.13M |
| 4 |
Clean Harbors
CLH
|
$6.6M |
| 5 |
Timken Company
TKR
|
$6.22M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Industrials | 46.25% |
| 2 | Healthcare | 42.59% |
| 3 | Technology | 3.29% |
| 4 | Materials | 2.86% |
| 5 | Financials | 2.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Crinetics Pharmaceuticals
CRNX
$3.26B
| $2.96M | 1.23% |
+57,933
| New | +$2.96M |
|
27
Amgen
AMGN
$153B
| $2.91M | 1.21% |
+11,179
| New | +$2.91M |
|
28
Gilead Sciences
GILD
$140B
| $2.85M | 1.18% |
+30,846
| New | +$2.85M |
|
29
Terex
TEX
$3.23B
| $2.84M | 1.18% |
+61,544
| New | +$2.84M |
|
30
argenx
ARGX
$44.2B
| $2.83M | 1.17% |
+4,598
| New | +$2.83M |
|
31
Ascendis Pharma
ASND
$12.1B
| $2.62M | 1.09% |
+19,040
| New | +$2.62M |
|
32
TSMC
TSM
$1.2T
| $2.25M | 0.93% |
+11,368
| New | +$2.25M |
|
33
Cytokinetics
CYTK
$5.98B
| $2.23M | 0.93% |
+47,383
| New | +$2.23M |
|
34
DexCom
DXCM
$30.9B
| $2.23M | 0.92% |
+28,643
| New | +$2.23M |
|
35
Incyte
INCY
$17B
| $2.1M | 0.87% |
+30,378
| New | +$2.1M |
|
36
Revolution Medicines
RVMD
$7.43B
| $1.99M | 0.83% |
+45,522
| New | +$1.99M |
|
37
Ionis Pharmaceuticals
IONS
$9.64B
| $1.99M | 0.83% |
+56,844
| New | +$1.99M |
|
|
BPMC
38
DELISTED
Blueprint Medicines
BPMC
| $1.96M | 0.81% |
+22,474
| New | +$1.96M |
|
39
Illumina
ILMN
$15.2B
| $1.9M | 0.79% |
+14,239
| New | +$1.9M |
|
40
Boston Scientific
BSX
$159B
| $1.83M | 0.76% |
+20,494
| New | +$1.83M |
|
41
Mirum Pharmaceuticals
MIRM
$3.75B
| $1.74M | 0.72% |
+41,968
| New | +$1.74M |
|
42
Intellia Therapeutics
NTLA
$1.26B
| $1.73M | 0.72% |
+148,167
| New | +$1.73M |
|
43
Union Pacific
UNP
$132B
| $1.69M | 0.7% |
+7,413
| New | +$1.69M |
|
44
Exelixis
EXEL
$9.95B
| $1.64M | 0.68% |
+49,256
| New | +$1.64M |
|
45
Edwards Lifesciences
EW
$47.7B
| $1.6M | 0.67% |
+21,635
| New | +$1.6M |
|
46
Masimo
MASI
$7.43B
| $1.58M | 0.66% |
+9,580
| New | +$1.58M |
|
47
Danaher
DHR
$143B
| $1.58M | 0.65% |
+6,869
| New | +$1.58M |
|
48
Insulet
PODD
$24.2B
| $1.41M | 0.58% |
+5,385
| New | +$1.41M |
|
49
Thermo Fisher Scientific
TMO
$183B
| $1.32M | 0.55% |
+2,534
| New | +$1.32M |
|
50
Moody's
MCO
$89B
| $1.24M | 0.51% |
+2,611
| New | +$1.24M |
|